Amrita Pati
Executive Director of Computational Biology, Precision Medicine, Amgen
Amrita Pati is Executive Director of Computational Biology in Precision Medicine at Amgen, where she leads efforts to integrate high-content clinical and biomarker data to accelerate therapeutic development across oncology, cardiometabolic diseases, inflammation, and rare disease. Her expertise spans multi-modal omics, liquid biopsy, AI/ML, and predictive analytics in Rx/Dx development. She oversees global biomarker and computational biology initiatives, integrating multi-omics, liquid biopsy, and advanced analytics to translate complex biology into actionable insights. Prior to Amgen, she directed algorithm development for oncology and NIPT NGS assays at Roche Sequencing and led the OMICs Analysis Group at the DOE Joint Genome Institute, where her team advanced multi-omics analyses for natural product biosynthesis and microbial genomics. Dr. Pati has authored more than 300 scientific publications and has contributed to the development and application of computational biology methods across diverse therapeutic areas. She holds a PhD in Computer Science with a specialization in Computational Biology and Bioinformatics from Virginia Tech.
Seminars
- Uncovering how inconsistent definitions, metrics, and data standards are hindering payer confidence and policy support for liquid biopsy
- Exploring the role of pre-competitive collaboration in driving standardization to unlock broader reimbursement and clinical adoption
- Identifying immediate policy actions and evidence needs to align stakeholders and accelerate access to serial testing and early detection
- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decisionmaking and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine
